What Clinigen does

Clinigen is a privately held pharmaceutical services company headquartered in Lismore, Ireland, founded in 2010 with 251–500 employees. Multiple third-party sources describe the company as a provider of pharmaceutical lifecycle services spanning clinical strategy, regulatory navigation, and global commercialization support for enterprise biotech innovators; one firmographic source characterizes it more narrowly as a pharmaceutical manufacturer serving retail pharmacies, hospitals, and wholesalers — a discrepancy that the rest of the corpus (which focuses on biotech-partner services, industry symposia, and commercialization partnerships) does not corroborate. The website (clinigengroup.ie) displays only a default hosting page, so no first-party product material is available.

The company's core offering is an end-to-end engagement model covering clinical strategy through global commercialization, delivered through direct enterprise field sales and amplified via industry symposia at major medical conferences. Its go-to-market targets clinical-stage and commercial-stage biotech innovators that lack internal commercialization infrastructure, including French biotech MaaT Pharma, for which Clinigen supports commercial activities around MaaT013 (acute graft-versus-host disease, currently under EMA review following an MAA submission in June 2025). Distribution is direct to enterprise buyers across global geographies, with the September 2025 acquisition of SSI Strategy adding approximately 200 employees and explicitly extending US and European coverage.

Clinigen earns revenue through professional services and managed-services engagements tied to client commercialization programs and strategic consulting mandates. Pricing is not publicly disclosed. The company operates within the $12–13 billion global pharmaceutical lifecycle services market, which third-party sources estimate will grow at roughly 10% annually through 2030. ESG positioning is part of the corporate profile: in December 2025 the company's greenhouse-gas reduction targets were validated by the Science Based Targets initiative, with a stated net-zero goal by 2040. Ownership structure, leadership beyond a single listed director (Colin Shannon), and revenue figures are not disclosed in the available data.

Name

Clinigen

Website

https://clinigengroup.ie

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

251–500 employees

Short description

Clinigen is a privately held Irish pharmaceutical services firm that provides clinical-strategy-to-commercialization support and strategic consulting to enterprise biotech innovators across global markets, including US and European geographies following its 2025 SSI Strategy acquisition.

Ownership category

akta.pro rank

Product category

Pharmaceutical Lifecycle Services

NAICS

Other Management Consulting Services (541618), Scientific Research and Development Services (5417)

SIC

Services-Management Consulting Services (8742), Pharmaceutical Preparations (2834)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

akta.pro secondary industries

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Pharmaceutical lifecycle services
• Biotech commercialization support
• Clinical strategy consulting
• Pharmaceutical market access
• Biotech strategic partnership

Headquarters

HQ city

Lismore

HQ country

Ireland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Lifecycle Services: Clinigen provides clinical strategy, commercialization support, and strategic consulting services to biotech innovators. The company operates in the $12-13 billion global pharmaceutical lifecycle services market expected to grow at nearly 10% annually through 2030.
2. Strategic Commercial Partnership: As strategic commercial partner, Clinigen supports biotech companies with product launches, market access, and commercialization activities including hosting industry symposia and supporting regulatory processes.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

Clinigen is a pharmaceutical services company that provides end-to-end pharmaceutical lifecycle services, spanning clinical strategy through global commercialization, for biotech innovators. The company operates as a strategic commercial partner, delivering clinical-strategy consulting, commercialization support, regulatory navigation, market access, and product-launch services to biotech and pharmaceutical companies globally. It expanded its capabilities and geographic reach with the September 2025 acquisition of SSI Strategy, a strategic consulting firm for biotech innovators.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Lifecycle Services End-to-end clinical-strategy, commercialization, market access, and product-launch support services for biotech innovators globally; covers seamless hand-off from clinical development into commercial stage across multiple regions.
• Strategic Commercial Partnership Services Long-form strategic commercial partnership engagements that combine product-launch support, market access, regulatory navigation, and industry-symposia activation at major medical conferences for clinical-stage biotech companies.
• SSI Strategy Strategic Consulting Strategic consulting services for biotech innovators covering clinical and commercialization support; brought into Clinigen's portfolio via the September 2025 acquisition of SSI Strategy.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• MaaT PharmacoreStrategic or Co-development Partner · 9 March 2026Clinigen serves as strategic commercial partner for MaaT Pharma, a French clinical-stage biotechnology company. Clinigen hosts industry symposia and supports commercialization activities for MaaT Pharma's hemato-oncology pipeline, including MaaT013 for acute graft-versus-host disease which is under EMA review following MAA submission in June 2025.
• SSI StrategycoreStrategic or Co-development Partner · 29 September 2025Clinigen acquired SSI Strategy, a strategic consulting firm for biotech innovators. The acquisition added 200 employees and deepened Clinigen's presence in US and European markets, reinforcing its role in the global pharmaceutical lifecycle services market.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Parexel International: Global CRO with strong regulatory, clinical, and commercialization capabilities serving biotech and pharma. Comparable as an end-to-end clinical-to-commercial services competitor.
• Lonza Group: Global CDMO providing development, manufacturing, and commercial services for biologics and small molecules. Comparable as a full-lifecycle services provider to pharma innovators.
• ICON plc: Major global CRO providing clinical research and commercialization services across all phases. Comparable to Clinigen in serving biotech innovators needing end-to-end support from clinical strategy through market launch.
• Thermo Fisher Scientific (PPD): Through PPD, offers clinical development and laboratory services to pharma and biotech. Comparable in serving biotech innovators seeking outsourced clinical and commercialization expertise.
• IQVIA: Global life sciences services giant offering clinical development, real-world evidence, and commercialization/launch services to biotech and pharma. Comparable to Clinigen as a large incumbent competing for the same pharma lifecycle services spend.
• Catalent: CDMO and pharma services partner supporting formulation, development, and commercial supply. Comparable to Clinigen's services-and-commercialization model for biotech innovator clients.
• Charles River Laboratories: Provides research models, preclinical/clinical CRO services, and manufacturing support to biotech innovators. Comparable as a life sciences services partner covering drug development lifecycle.

Direct peers

• Syneos Health: Biopharma solutions organization combining clinical development with commercial/launch services. Closely comparable to Clinigen's 'clinical strategy to commercialization' positioning and biotech-focused customer base.
• ProPharma Group: Regulatory, compliance, and pharmacovigilance consulting firm serving pharma and biotech. Comparable as a focused medical affairs/regulatory services peer addressing the same late-stage commercialization challenges.
• PharmaLex (now part of Cencora): Specialized regulatory affairs, pharmacovigilance, and medical affairs consulting provider for biotech and pharma. Directly comparable to Clinigen's regulatory strategy and medical affairs support offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinigen